Signal
Following an FDA marketing suspension, Valneva has decided to voluntarily withdraw its chikungunya vaccine Ixchiq in the U.S. The FDA has also opened an inve...
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-01-20 16:47 UTCUpdated 2026-01-20 18:00 UTC
rss
regulationfierce_pharma
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
The decision comes months after the FDA had suspended the vaccine’s license. One analyst speculated the company might shelve the product altogether.
Score total
1
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
All evidence
All evidence
Following an FDA marketing suspension, Valneva has decided to voluntarily withdraw its chikungunya vaccine Ixchiq in the U.S. The FDA has also opened an investigation into a new...
Fierce Pharma (All) · fiercepharma.com · 2026-01-20 18:00 UTC
Valneva to withdraw Chikungunya vaccine from US amid safety woes
BioPharma Dive (Latest) · biopharmadive.com · 2026-01-20 16:47 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Pharma (All) (1)
- BioPharma Dive (Latest) (1)
Top origin domains (this list)
- fiercepharma.com (1)
- biopharmadive.com (1)